The nucleolin-binding G-quadruplex AS1411 aptamer has been widely used for cancer therapy and diagnosis and linked to nanoparticles for its selective targeting activity. We applied a computational and experimental integrated approach to study the effect of engineering AS1411 aptamer on an octahedral truncated DNA nanocage to obtain a nanostructure able to combine selective cancer-targeting and anti-tumor activity. The nanocages functionalized with one aptamer molecule (Apt-NC) displayed high stability in serum, were rapidly and selectively internalized in cancer cells through an AS1411-dependent mechanism, and showed over 200-fold increase in anti-cancer activity when compared with the free aptamer. Comparison of Apt-NCs and free AS1411 intracellular distribution showed that they traffic differently inside cells: Apt-NCs distributed through the endo-lysosomal pathway and were never found in the nuclei, while the free AS1411 was mostly found in the perinuclear region and in nucleoli. Molecular dynamics simulations indicated that the aptamer, when linked to the nanocage, sampled a limited conformational space, more confined than in the free state, which is characterized by a large number of metastable conformations. A different intracellular trafficking of Apt-NCs compared with free aptamer and the confined aptamer conformations induced by the nanocage were likely correlated with the high cytotoxic enhancement, suggesting a structure–function relationship for the AS1411 aptamer activity.

Vindigni, G., Raniolo, S., Iacovelli, F., Unida, V., Stolfi, C., Desideri, A., et al. (2021). Aptamer linked to DNA nanostructures diverts its traffic inside cancer cells and improves its therapeutic efficacy. PHARMACEUTICS, 13(10) [10.3390/pharmaceutics13101671].

Aptamer linked to DNA nanostructures diverts its traffic inside cancer cells and improves its therapeutic efficacy

Vindigni G;Raniolo S;Iacovelli F;Unida V;Stolfi C;Desideri A;Biocca S.
2021-01-01

Abstract

The nucleolin-binding G-quadruplex AS1411 aptamer has been widely used for cancer therapy and diagnosis and linked to nanoparticles for its selective targeting activity. We applied a computational and experimental integrated approach to study the effect of engineering AS1411 aptamer on an octahedral truncated DNA nanocage to obtain a nanostructure able to combine selective cancer-targeting and anti-tumor activity. The nanocages functionalized with one aptamer molecule (Apt-NC) displayed high stability in serum, were rapidly and selectively internalized in cancer cells through an AS1411-dependent mechanism, and showed over 200-fold increase in anti-cancer activity when compared with the free aptamer. Comparison of Apt-NCs and free AS1411 intracellular distribution showed that they traffic differently inside cells: Apt-NCs distributed through the endo-lysosomal pathway and were never found in the nuclei, while the free AS1411 was mostly found in the perinuclear region and in nucleoli. Molecular dynamics simulations indicated that the aptamer, when linked to the nanocage, sampled a limited conformational space, more confined than in the free state, which is characterized by a large number of metastable conformations. A different intracellular trafficking of Apt-NCs compared with free aptamer and the confined aptamer conformations induced by the nanocage were likely correlated with the high cytotoxic enhancement, suggesting a structure–function relationship for the AS1411 aptamer activity.
2021
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore BIO/12 - BIOCHIMICA CLINICA E BIOLOGIA MOLECOLARE CLINICA
Settore BIOS-09/A - Biochimica clinica e biologia molecolare clinica
English
Con Impact Factor ISI
Vindigni, G., Raniolo, S., Iacovelli, F., Unida, V., Stolfi, C., Desideri, A., et al. (2021). Aptamer linked to DNA nanostructures diverts its traffic inside cancer cells and improves its therapeutic efficacy. PHARMACEUTICS, 13(10) [10.3390/pharmaceutics13101671].
Vindigni, G; Raniolo, S; Iacovelli, F; Unida, V; Stolfi, C; Desideri, A; Biocca, S
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
pharmaceutics-13-01671-v2.pdf

accesso aperto

Tipologia: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 2.46 MB
Formato Adobe PDF
2.46 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/283691
Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus 25
  • ???jsp.display-item.citation.isi??? 24
social impact